The Danish drugmaker, which is grappling with a share decline and competition from Eli Lilly, unveiled planned trials of an ...

Like in the STRIDE study of PAD, GLP-1s improved outcomes, but more work is needed to clarify who may benefit most.

Metsera is advancing promising obesity treatments with amylin and GLP-1 analogs, eyeing competitive efficacy and buyout ...

FROM eggy burps to stomach-churning nausea, there appears to be an endless list of side effects linked to Ozempic-like jabs.

A clash is brewing between doctors and patients when it comes to treatment for sleep apnea in those with obesity, a new study ...

Early-stage study results suggest that a single shot of the company’s therapy, which works differently than GLP-1 medicines, ...

Body image is part physical and part mental. If weight loss alone isn't helping, strategies from body image psychology can ...

Fifteen Connecticut companies made the 2025 Fortune 500 list of the largest U.S. corporations, which was announced Monday-- a sign of stability in the state's corporate sector. Bloomfield- ...

Excess body weight can raise the risk of certain cancers, leading researchers to wonder whether blockbuster drugs like Wegovy, Ozempic ...

A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...

Donation Options Search Search Search Boxes of the weight-loss medications Wegovy and Zepbound. JoNel Aleccia ... data from 43 U.S. health systems to compare two groups: people with obesity ...

As the Food and Drug Administration clamps down on off-brand weight loss medications ... blockbuster medications like Ozempic, Wegovy and Zepbound skyrocketed. These drugs are typically prescribed ...